<DOC>
	<DOCNO>NCT00478270</DOCNO>
	<brief_summary>This single arm study ass efficacy load dos intravenous Bondronat reduce pain patient breast cancer metastatic bone disease experience moderate severe bone pain . Patients receive intravenous infusion 6mg Bondronat day 1 , 2 3 . The anticipated time study treatment &lt; 3 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Loading Doses Intravenous Bondronat ( Ibandronate ) Patients With Breast Cancer Metastatic Bone Disease .</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; breast cancer ; bone metastases ; mean bad pain score &gt; =4 3 day baseline period ; stable dose analgesic 3 day baseline period ; adequate renal function . bisphosphonate treatment within 3 week study enrollment ; change antineoplastic treatment within 6 week study enrollment ; bone radiation within 2 week study enrollment ; active infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>